Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE).
Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields.
This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for newly diagnosed glioblastoma. All patients received simultaneous scalp-sparing radiation (60 Gy in 30 fractions), normal concomitant temozolomide (75 mg / m2 daily), and TTFields. Maintenance treatment included normal temozolomide, and TTF field continuity.